CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Nintedanib 150 MGWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug616 Placebo Wiki 0.10

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D011658 Pulmonary Fibrosis NIH 0.58

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Efficacy and Safety of Nintedanib Ethanesulfonate Soft Capsule in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID-9(COVID 19) : a Single-center, Randomized, Placebo-controlled Study

This center intends to conduct a single-center, randomized, placebo-controlled study to evaluate the effectiveness and safety of Nintedanib ethanesulfonate soft capsule in the treatment of pulmonary fibrosis in patients with moderate to severe COVID-19.

NCT04338802 COVID-19 Nintedanib Safety Effect of Drugs Drug: Nintedanib 150 MG Other: Placebo
MeSH:Pulmonary Fibrosis
HPO:Pulmonary fibrosis

Primary Outcomes

Description: Changes in forced vital capacity (FVC) after treatment compared to baseline.

Measure: Changes in forced vital capacity (FVC)

Time: 8 weeks

Secondary Outcomes

Description: Changes incarbon monoxide dispersion (DLco%) after treatment compared to baseline.

Measure: Changes in carbon monoxide dispersion (DLco%)

Time: 8 weeks

Description: Changes in the six-minute walk test (6MWT) after treatment compared to baseline.

Measure: Changes in the six-minute walk test (6MWT)

Time: 8 weeks

Description: Changes in High resolution CT score after treatment compared to baseline.The minimum and maximum values are 0 and 25 , and higher scores mean a worse outcome. As for the score, it is the expected value and will be determined according to the actual result

Measure: Changes in High resolution CT score

Time: 8 weeks

Related HPO nodes (Using clinical trials)

HP:0002206: Pulmonary fibrosis
Genes 80
HLA-DPA1 RCBTB1 PSMC3IP HLA-DRB1 PTPN22 CASP10 POLR3H TERT HLA-DRB1 SP110 HPS4 CLCA4 CCN2 ASAH1 FAM111B TINF2 SFTPA1 MUC5B ATP11A ABCA3 TERT RNF168 KIAA0319L TERT TERT MUC5B RASGRP1 PLEC HLA-DPB1 NUP107 NOP10 NKX2-1 CCR6 THOC2 PRKCD NHP2 DPP9 STX1A RTEL1 TERC HLA-DRB1 DSP FAS DKC1 DCTN4 NR5A1 PARN FAM13A FAS CCR6 TGFB1 CAV1 AP3B1 TERC SFTPC IRF5 BTNL2 CAV1 ALMS1 TERT HPS1 SFTPA2 STN1 SPIDR FASLG CTLA4 RTEL1 SFTPC SFTPA2 BMP15 PARN PRTN3 MRPS22 TINF2 CFTR RNF168 IRF5 FSHR CCN2 TERC
Protein Mutations 1
V600E
SNP 1
rs35705950